APG-2575 (Lisaftoclax)
Leukemias & additional blood cancers
Key Facts
About Ascentage Pharma
Ascentage Pharma is a clinical-stage biotech with a unique focus on restoring apoptosis in cancer cells through a portfolio of novel small molecule inhibitors. Its pipeline includes candidates targeting Bcl-2, Bcl-2/Bcl-xL, IAP, and MDM2-p53 pathways, as well as next-generation TKIs, with multiple assets in international registrational trials. The company actively seeks global partnerships to accelerate development and commercialization. With a deep scientific foundation and a late-stage clinical pipeline, Ascentage aims to address significant unmet needs in oncology.
View full company profileAbout Ascentage Pharma Group
Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.
View full company profileAbout Ascentage Pharma Group
Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.
View full company profileAbout Ascentage Pharma Group
Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.
View full company profile